To discuss the chemistry, pharmacokinetics, spectrum of activity, clinical trials, adverse effects, drug interactions, and dosage guidelines of cefpodoxime proxetil.
DATA SOURCES:
Literature was identified through a MEDLINE search from 1988 to the present and from review of bibliographies in that literature.
STUDY SELECTION:
Data were limited to comparative trials published in the English literature. Although many studies were conducted in Japan, the results often were available only in Japanese or partly in English. As these studies could not be completely evaluated, they are not included in this review.
DATA SYNTHESIS:
Cefpodoxime exhibits good activity against many gram-positive and gram-negative organisms. In clinical trials, cefpodoxime was similar in both clinical and bacteriologic efficacy to amoxicillin, cefaclor, amoxicillin/clavulanate, and penicillin in the treatment of respiratory and urinary tract infections. It also appeared effective in the treatment of skin and soft tissue infections, although no comparative trials have been performed. Cefpodoxime is well tolerated by children and is effective in the treatment of otitis media and pharyngitis. It has a similar adverse effect profile to that of other penicillins and cephalosporins, with gastrointestinal effects being most common.
CONCLUSIONS:
Cefpodoxime demonstrates good in vitro activity against pathogens frequently associated with respiratory tract, urinary tract, and skin and tissue infections. It has not demonstrated greater efficacy than the other antibiotics to which it has been compared. The available published clinical trials are fraught with methodologic, statistical, and evaluative flaws. Thus, further trials comparing cefpodoxime with established treatments, as well as the newer cephalosporins, are needed before its place in therapy can be established.
Get full access to this article
View all access options for this article.
References
1.
DabernatHAvrilJLBoussougantY. In vitro activity of cefpodoxime against pathogens responsible for community-acquired respiratory tract infections. J Antimicrob Chemother1990; 26 (suppl E): l–6.
2.
BorinMT. A review of the pharmacokinetics of cefpodoxime proxetil. Drugs1991; 42 (suppl 3): 13–21.
YokotaTSuzukiEAraiK. Cefpodoxime proxetil, its in vitro antibacterial activity, affinity to bacterial penicillin-binding proteins, and synergy of bactericidal activity with serum complement and mouse-cultured macrophages. Drug Exp Clin Res1988; 14: 495–500.
5.
BorinMTHughesGSPatelRKRoyerMECathcartKS. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil. J Clin Pharmacol1991; 31: 1137–45.
6.
TremblayDDuprontAHoCCoussediereDLenfantB. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses. J Antimicrob Chemother1990; 26 (suppl E): 21–8.
7.
HughesGSHealdDLBarkerKBPatelRKSpillersCRWattsKCThe effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther1989; 46: 674–85.
8.
FujiiR. Clinical trials of cefpodoxime proxetil suspension in paediatrics. Drugs1991; 42 (suppl 3): 57–60.
9.
TheopoldHMMatthiasCAdamD. Cefpodoxime proxetil concentrations in head and neck tissues. Infection1991; 19: 41–3.
10.
GehannoPAndrewsJMIchouFSultanELenfantB. Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil. J Antimicrob Chemother1990; 26 (suppl E): 47–51.
11.
CouraudLAndrewsJMLecoeurHSultanELenfantB. Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil. J Antimicrob Chemother1990; 26 (suppl E): 35–40.
12.
Muller-SerieysCBancalCDombretMCSolerPMurcianoGAubierMPenetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients. Antimicrob Agents Chemother1992; 36: 2099–103.
13.
DumontRGuetatFAndrewsJMSultanELenfantB. Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil. J Antimicrob Chemother1990; 26 (suppl E): 41–6.
14.
BorinMTHughesGSSpillersCRPatelRK. Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil. Antimicrob Agents Chemother1990; 34: 1094–9.
15.
O'NeillPNyeKDouceGAndrewsJWiseR. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers. Antimicrob Agents Chemother1990; 34: 232–4.
16.
NaberKGKinzigMAdamDSörgelFBajorskiAHKiehnR. Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue. Infection1991; 19: 30–9.
17.
BackhouseCWadeAWilliamsonPTremblayDLefantB. Multiple dose pharmacokinetics of cefpodoxime in young adult and elderly patients. J Antimicrob Chemother1990; 26 (suppl E): 29–34.
18.
St PeterJVBorinMTHughesGSKellowayJSShapiroBEHalstensonCE. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function. Antimicrob Agents Chemother1992; 36: 126–31.
19.
BorinMTHughesGSKellowayJSShapiroBEHalstensonCE. Disposition of cefpodoxime proxetil in hemodialysis patients. J Clin Pharmacol1992; 32: 1038–44.
20.
HöfflerDKoeppePCorciliusMPrzyklinkA. Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis. Infection1990; 18: 157–62.
21.
KnotheHShahPMEckardtO. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity. Infection1991; 19: 370–5.
22.
WiedemannBLuhmerEZühlsdorfMT. In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci, enter-obacteriaceae and Pseudomonas aeruginosa, including beta-lactamase producers. Infection1991; 19: 363–9.
23.
BauernfeindAJungwirthR. In vitro evaluation of cefpodoxime, a new oral cephalosporin of the third generation. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefproxil, BAY 3522, cefuroxime, cefaclor and cefadroxil. Infection1991; 19: 353–62.
SarubbiFAVergheseACaggianoCHoltsclaw-BerkSBerkSL. In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother1989; 33: 113–4.
26.
FeketeTWoodwellJCundyKR. Susceptibility of Neisseria gonorrhoeae to cefpodoxime: determination of MICs and disk diffusion zone diameters. Antimicrob Agents Chemother1991; 35: 497–9.
27.
ClendennenTEHamesCSKeesESPriceFCRueppelWJAndradaABIn vitro antibiotic susceptibilities of Neisseria gonorrhoeae isolates in the Philippines. Antimicrob Agents Chemother1992; 36: 277–82.
28.
WernerHHeizmannWRHöflsauerM. Comparative in vitro activity of cefpodoxime against anaerobes other than Bacteriodes fragilis. Infection1991; 19: 377–9.
29.
JonesRNBarryAL. Antimicrobial activity and disk diffusion susceptibility testing of U-76,253 (R-3746), the active metabolite of the new cephalosporin ester 76,252 (CS-807). Antimicrob Agents Chemother1988; 32: 443–9.
30.
GehannoPDepondtJBarryBSimonetMDeweverH. Comparison of cefpodoxime proxetil with cefaclor in the treatment of sinusitis. J Antimicrob Chemother1990; 26 (suppl E): 87–91.
31.
MendelmanPMDel BeccaroMAMcLinnSEToddWM. Cefpodoxime proxetil compared with amoxicillin-clavulanate for the treatment of otitis media. J Pediatr1992; 121: 459–65.
32.
PortierHChavanetPGouyonJBGuetatF. Five day treatment of pharyngotonsillitis with cefpodoxime proxetil. J Antimicrob Chemother1990; (suppl E): 79–85.
33.
BrownRJBattsDHHughesGS, Greenwald CA, and the Cefpodoxime Pharyngitis Study Group. Comparison of oral cefpodoxime proxetil and penicillin V potassium in the treatment of group A streptococcal pharyngitis/tonsillitis. Clin Ther1991; 13: 579–88.
34.
PeritiPNovelliASchildwachterGSchmidt-GaykHRyoYZuckP. Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis. J Antimicrob Chemother1990; 26 (suppl E): 63–9.
35.
ZuckPRioYIchouF. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J Antimicrob Chemother1990; 26 (suppl E): 71–7.
36.
CoxCEGravelineJFLuongoJM. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections. Drugs1991; 42 (suppl 3): 41–50.
37.
TackKJWilksNESemerdjianGFrazierCHShirinKPuopoloACefpodoxime proxetil in the treatment of skin and soft tissue infections. Drugs1991; 42 (suppl 3): 51–6.
38.
BonwellLO'KeefePLibertinC. Comparison of cefpodoxime and ceftriaxone in uncomplicated gonococcal infection (abstract). Proceedings of the 90th annual meeting of the American Society for Microbiology 1990, Anaheim, CA, May 13–17, 1990. Am Soc Microbiol1990: 90: 17.
39.
SafranC. Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections. J Antimicrob Chemother1990; 26 (suppl E): 93–101.
40.
SaathoffNLodeHNeiderKDeppermanKMBornerKKoeppeP. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother1992; 36: 796–800.
41.
HughesGSHealdDLPatelRSpillersCRBattsDHEulerAR. Gastric emptying and the pharmacokinetics of the cephalosporin antibiotic, cefpodoxime proxetil. Meth Find Exp Clin Pharmacol1990; 12: 197–204.
